RBC Capital Initiates Coverage on Genzyme (GENZ) with an Outperform
More News related to GENZ
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
- PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
RBC Capital initiates coverage on Genzyme (Nasdaq: GENZ) with an Outperform rating.
To see more analyst ratings on GENZ Click Here.
Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology.
Related Categories
New CoverageStocks Mentioned
+0.26Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
